418 results on '"Korn, Stephanie"'
Search Results
2. Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany
3. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
4. Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review
5. German Asthma Net – Was haben wir bisher gelernt?
6. Initiation, response assessment, and switch of antibody therapies in patients with severe asthma – A survey among German specialists
7. Characterization of Austrian severe asthma patients
8. Characterization of Obesity in Severe Asthma in the German Asthma Net
9. Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe Asthma Registry Cohort
10. Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
11. German asthma net: Nasal polyposis in patients in the severe asthma registry
12. Overall Response to Anti-IL-5/Anti-IL5-Rα Treatment in Severe Asthma Does Not Depend on Initial Bronchodilator Responsiveness
13. Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
14. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
15. Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma
16. The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control
17. Validation of the German version of the Asthma Impairment and Risk Questionnaire (AIRQ).
18. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years
19. As-needed low-dose inhaled corticosteroid/formoterol therapy in patients with severe asthma included in the German Asthma Net cohort
20. Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma
21. Age- and sex-dependent differences in patients with severe asthma included in the German Asthma Net cohort
22. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study
23. Tezepelumab in patients with allergic and eosinophilic asthma
24. Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT Study
25. Pioneering a paradigm shift in asthma management: remission as a treatment goal
26. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab
27. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study
28. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps
29. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
30. Tezepelumab in patients with allergic and eosinophilic asthma.
31. Long-Term Dupilumab Efficacy on Severe Exacerbations and Lung Function in Patients with Type 2 Asthma.
32. Characteristics of exacerbations in patients with severe, uncontrolled asthma who received tezepelumab versus placebo
33. Initiation, response assessment and switch of antibody therapies in patients with severe asthma – a survey among German specialists
34. Tezepelumab can restore normal lung function in patients with severe, uncontrolled asthma
35. Late Breaking Abstract - SHAMAL: reduction of maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab: a randomised phase 4 study
36. Response to biologics and clinical remission in the adult GAN severe asthma cohort.
37. German Asthma Net: Nasal polyposis in patients with severe asthma
38. Impact of smoking on biologicals treatment response in patients from the German Severe Asthma (GAN) Registry
39. Reply to Lipworth and Chan
40. Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials
41. Pioneering a paradigm shift in asthma management: remission as a treatment goal.
42. Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT Study.
43. Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)
44. Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)
45. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
46. Assessing biomarkers in a real-world severe asthma study (ARIETTA)
47. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline
48. The German Asthma Net: Anti-IL5(R) therapy reduces disease burden in a real-life severe asthma cohort in comparison to patients on maintenance OCS therapy
49. Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma.
50. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.